Amgen beats estimates but shares dip on biosimilar concerns
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Amgen Inc (NASDAQ:AMGN) reported third quarter results that exceeded Wall Street expectations, but shares fell 1.5% in after-hours trading Tuesday as investors weighed the impact of biosimilar competition on key products. Still guessing which stocks will beat…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishEarnings beat expectations, but shares fell after hours on biosimilar competition for key products.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Amgen reported adjusted EPS of $6.45 versus $5.76 consensus.
- 02Revenue rose 8% year over year to $10.4 billion, above the $10.06 billion estimate.
- 03Biosimilar concerns for Prolia and XGEVA overshadowed the results.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets